

Temporary benefits added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of Mint-Spironolactone 25 mg Tablet (DIN 02488140) manufactured by Mint Pharmaceuticals Inc., Teva-Spironolactone 25 mg Tablet (DIN 00613215) manufactured by Teva Canada Limited and the current temporary benefit, Jamp Spironolactone 25 mg Tablet (DIN 02518821) manufactured by Jamp Pharma Corporation, Aldactone 25 mg Tablet (DIN 00028606) manufactured by Pfizer Canada ULC, will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was previously added to the Critical Supply Product List on **September 13, 2022**.

As of **October 19, 2022**, all claims for Aldactone 25 mg Tablet (DIN 00028606) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The ABCDPL is available online at ab.bluecross.ca/providers/pharmacy-home.php.

Due to the unavailability of Hydromorphone HP 10 mg/ml Injection (DIN 02145928) manufactured by Sandoz Canada Inc., Hydromorphone HCL HP 10 mg/ml Injection (DIN 02460610) manufactured by Sterimax Inc., will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List on **October 20, 2022**.

As of **October 20, 2022**, all claims for Hydromorphone HCL HP 10 mg/ml Injection (DIN 02460610) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The ABCDPL is available online at ab.bluecross.ca/providers/pharmacy-home.php.

Removal of temporary benefit from the *ADBL*

Due to the shortage of Nardil 15 mg Tablet (DIN 00476552) manufactured by ERFA Canada 2012 Inc., Phenelzine Sulfate USP 15 mg Tablet (PIN 09858123) manufactured by Lupin Pharma Canada Limited was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

ERFA Canada 2012 Inc. has advised Alberta Blue Cross that the shortage for Nardil 15 mg Tablet (DIN 00476552) has been resolved.

Phenelzine Sulfate USP 15 mg Tablet (PIN 09858123) will no longer be considered a temporary benefit for the *ADBL* after **November 26, 2022**. The above grouping was removed from the Critical Supply Product List on **October 26, 2022**.

continued next page

continued from previous page

Product supply shortage addressed for **ADBL**

Alberta Blue Cross has been advised by Purdue Pharma that the shortage for MS.IR 5 mg Tablet (DIN 02014203) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and, as a result, the LCA price policy will be reapplied to the following grouping effective **November 28, 2022**. The following grouping was removed from the Critical Supply Product List on **October 26, 2022**.

MORPHINE SULFATE

5 MG TABLET

00002014203	MS.IR	PUR	\$ 0.1100
00000594652	STATEX	PAL	\$ 0.1168

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

